Evidence map›Paper›PMID 41492280›Full record

ArticleInternational journal of pharmaceutics: X2025

Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer's disease.

Rudy Chang, Devaraj V Chandrashekar, G Chuli Roules, Nataraj Jagadeesan, Emi Iwasaki, Adenike Oyegbesan, Hayk Davtyan, Rachita K Sumbria

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Rudy ChangDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA 92618, USA.
Devaraj V ChandrashekarDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA 92618, USA.
G Chuli RoulesDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA 92618, USA.
Nataraj JagadeesanDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA 92618, USA.
Emi IwasakiSchmid College of Science and Technology, 1 University Dr, Orange, CA 92866, USA.
Adenike OyegbesanDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA 92618, USA.
Hayk DavtyanMIND Institute, University of California, Irvine, CA 92697, USA.
Rachita K SumbriaDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA 92618, USA.

Funding

A Brain Penetrating Bi-functional Transferrin Receptor Antibody-TNF-alpha Decoy Receptor Fusion Protein for Alzheimer's DiseaseR01AG062840 · NIA · KECK GRADUATE INST OF APPLIED LIFE SCIS · PI SUMBRIA, RACHITA · 2019 to 2024
$1.9M
Efficacy, safety, and mechanisms of brain penetrable erythropoietin in Alzheimer’s disease mouse modelsR01AG085724 · NIA · CHAPMAN UNIVERSITY · PI Rachita Sumbria · 2024 to 2026
$1.0M
NIA NIH HHS R01 AG062840NIA NIH HHS R01 AG085724
6 · The paper itself

Abstract

Erythropoietin (EPO) shows promise for Alzheimer's disease (AD) but has poor brain penetration, necessitating high doses that cause hematopoietic side effects. To improve brain delivery, EPO was fused to a transferrin receptor monoclonal antibody (TfRMAb), and this study evaluated the pharmacokinetics (PK), safety, and efficacy of repeated TfRMAb-EPO dosing in mice to further its preclinical development. C57BL/6J male mice (10 weeks old,

Indexed as

Alzheimer's diseaseAPPSAA KI miceBlood-brain barrierErythropoietinPharmacokineticsTransferrin receptor antibody

Identifiers

PMID41492280
PMCPMC12765438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.